Federal antitrust regulators are holding back from challenging efforts by Centene Corp. to acquire New York State Catholic Health Plan Inc., which does business as Fidelis Care.
The U.S. Federal Trade Commission let the usual federal antitrust review waiting period expire early, Centene announced Monday.
Early termination of the waiting period could help ease Centene’s move into the New York state Medicaid plan and individual health markets.
Centene, a St. Louis-based company, announced in September that it has agreed to pay $3.75 billion for “substantially all of the assets” of Fidelis Care.
Fidelis Care is a major player in New York state’s Medicaid plan, Children’s Health Insurance Program (CHIP) and individual major medical markets, including the Affordable Care Act public exchange market.